Literature DB >> 20032217

Immunologic indicators of clinical progression during canine Leishmania infantum infection.

Paola M Boggiatto1, Amanda E Ramer-Tait, Kyle Metz, Erin E Kramer, Katherine Gibson-Corley, Kathleen Mullin, Jesse M Hostetter, Jack M Gallup, Douglas E Jones, Christine A Petersen.   

Abstract

In both dogs and humans Leishmania infantum infection is more prevalent than disease, as infection often does not equate with clinical disease. Previous studies additively indicate that advanced clinical visceral leishmaniasis is characterized by increased production of anti-Leishmania antibodies, Leishmania-specific lymphoproliferative unresponsiveness, and decreased production of gamma interferon (IFN-gamma) with a concomitant increase of interleukin-10 (IL-10). In order to differentiate infection versus progressive disease for better disease prognostication, we temporally evaluated humoral and cellular immunologic parameters of naturally infected dogs. The work presented here describes for the first time the temporal immune response to natural autochthonous L. infantum infection in foxhounds within the United States. Several key changes in immunological parameters should be considered when differentiating infection versus clinical disease, including a dramatic rise in IgG production, progressive increases in antigen-specific peripheral blood mononuclear cell proliferation, and IFN-gamma production. Polysymptomatic disease is precluded by increased IL-10 production and consistent detection of parasite kinetoplast DNA in whole blood. This clinical presentation and the immuno-dysregulation mirror those observed in human patients, indicating that this animal model will be very useful for testing immunomodulatory anti-IL-10 and other therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032217      PMCID: PMC2815526          DOI: 10.1128/CVI.00456-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  34 in total

Review 1.  Science, medicine, and the future: Leishmaniasis.

Authors:  L J Roberts; E Handman; S J Foote
Journal:  BMJ       Date:  2000-09-30

2.  Visceral leishmaniasis in a New York foxhound kennel.

Authors:  Amanda A Gaskin; Peter Schantz; Joan Jackson; Adam Birkenheuer; Lindsay Tomlinson; Marina Gramiccia; Michael Levy; Frank Steurer; Eleanor Kollmar; Barbara C Hegarty; Albert Ahn; Edward B Breitschwerdt
Journal:  J Vet Intern Med       Date:  2002 Jan-Feb       Impact factor: 3.333

3.  IL-10 mediates susceptibility to Leishmania donovani infection.

Authors:  M L Murphy; U Wille; E N Villegas; C A Hunter; J P Farrell
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

4.  IgG subclass responses in a longitudinal study of canine visceral leishmaniasis.

Authors:  R J Quinnell; O Courtenay; L M Garcez; P M Kaye; M A Shaw; C Dye; M J Day
Journal:  Vet Immunol Immunopathol       Date:  2003-02-10       Impact factor: 2.046

5.  IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection.

Authors:  D E Jones; L U Buxbaum; P Scott
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

6.  Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection.

Authors:  Douglas E Jones; Mark R Ackermann; Ulrike Wille; Christopher A Hunter; Phillip Scott
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

7.  Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial.

Authors:  A S Mazloumi Gavgani; M H Hodjati; H Mohite; C R Davies
Journal:  Lancet       Date:  2002-08-03       Impact factor: 79.321

8.  Cytokine expression in dogs with natural Leishmania infantum infection.

Authors:  M A Panaro; O Brandonisio; A Cianciulli; P Cavallo; V Lacasella; P Paradies; G Testini; D De Caprariis; V Mitolo; D Otranto
Journal:  Parasitology       Date:  2009-06-02       Impact factor: 3.234

9.  High antigen levels are the cause of T cell exhaustion during chronic viral infection.

Authors:  Scott N Mueller; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-11       Impact factor: 11.205

Review 10.  Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis.

Authors:  L Solano-Gallego; A Koutinas; G Miró; L Cardoso; M G Pennisi; L Ferrer; P Bourdeau; G Oliva; G Baneth
Journal:  Vet Parasitol       Date:  2009-06-06       Impact factor: 2.738

View more
  37 in total

1.  Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.

Authors:  Sita S Withers; Peter F Moore; Hong Chang; Jin W Choi; Stephen J McSorley; Michael S Kent; Arta M Monjazeb; Robert J Canter; William J Murphy; Ellen E Sparger; Robert B Rebhun
Journal:  Dev Comp Immunol       Date:  2018-05-31       Impact factor: 3.636

Review 2.  One health: the importance of companion animal vector-borne diseases.

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

3.  Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial.

Authors:  Angela Toepp; Mandy Larson; Tara Grinnage-Pulley; Carolyne Bennett; Michael Anderson; Molly Parrish; Hailie Fowler; Geneva Wilson; Katherine Gibson-Corely; Radhika Gharpure; Caitlin Cotter; Christine Petersen
Journal:  Am J Trop Med Hyg       Date:  2018-03-01       Impact factor: 2.345

4.  Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL.

Authors:  Mandy Larson; Angela Toepp; Benjamin Scott; Melissa Kurtz; Hailie Fowler; Javan Esfandiari; Randall F Howard; Aarthy C Vallur; Malcolm S Duthie; Christine Petersen
Journal:  Appl Microbiol Biotechnol       Date:  2016-10-31       Impact factor: 4.813

5.  Activation of autophagy and nucleotide-binding domain leucine-rich repeat-containing-like receptor family, pyrin domain-containing 3 inflammasome during Leishmania infantum-associated glomerulonephritis.

Authors:  Kevin J Esch; Robert G Schaut; Ian M Lamb; Gwendolyn Clay; Ádila L Morais Lima; Paulo R P do Nascimento; Elizabeth M Whitley; Selma M B Jeronimo; Fayyaz S Sutterwala; Joseph S Haynes; Christine A Petersen
Journal:  Am J Pathol       Date:  2015-06-13       Impact factor: 4.307

6.  Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function.

Authors:  Kevin J Esch; Rachel Juelsgaard; Pedro A Martinez; Douglas E Jones; Christine A Petersen
Journal:  J Immunol       Date:  2013-10-23       Impact factor: 5.422

7.  Leishmania-Derived Trimannose Modulates the Inflammatory Response To Significantly Reduce Leishmania major-Induced Lesions.

Authors:  Tara L Grinnage-Pulley; Daniel E K Kabotso; Chelsea L Rintelmann; Rajarshi Roychoudhury; Robert G Schaut; Angela J Toepp; Katherine N Gibson-Corley; Molly Parrish; Nicola L B Pohl; Christine A Petersen
Journal:  Infect Immun       Date:  2017-12-19       Impact factor: 3.441

8.  Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.

Authors:  Robert G Schaut; Tara L Grinnage-Pulley; Kevin J Esch; Angela J Toepp; Malcolm S Duthie; Randall F Howard; Steven G Reed; Christine A Petersen
Journal:  Vaccine       Date:  2016-09-21       Impact factor: 3.641

9.  Immunologic progression of canine leishmaniosis following vertical transmission in United States dogs.

Authors:  Blake Vida; Angela Toepp; Robert G Schaut; Kevin J Esch; Rachel Juelsgaard; Raeann M Shimak; Christine A Petersen
Journal:  Vet Immunol Immunopathol       Date:  2015-12-02       Impact factor: 2.046

10.  Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.

Authors:  Robert G Schaut; Ian M Lamb; Angela J Toepp; Benjamin Scott; Carolina O Mendes-Aguiar; Jose F V Coutinho; Selma M B Jeronimo; Mary E Wilson; John T Harty; Thomas J Waldschmidt; Christine A Petersen
Journal:  J Immunol       Date:  2016-04-13       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.